A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction

Investigational New Drugs

Volumn 30, Issue 4, 2012, Pages 1684-1689

  Adelstein, David J ^a   Rodriguez, Cristina P ^a   Rybicki, Lisa A ^b   Ives, Denise I ^a   Rice, Thomas W ^b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

EGFR inhibitors; Esophageal cancer; Gastroesophageal cancer; Gefitinib

Indexed keywords

GEFITINIB;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FATIGUE; FEMALE; HUMAN; LOWER ESOPHAGUS SPHINCTER ADENOCARCINOMA; LOWER ESOPHAGUS SPHINCTER SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; STOMATITIS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PATIENT COMPLIANCE; QUINAZOLINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84866733910     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9736-z     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277-300
2. Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349:2241-2252
3. Ilson DH, Ajani J, Bhalla K et al (1998) Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16:1826-1834
4. El-Rayes BF, Shields A, Zalupski M et al (2004) A phase II study of carboplatin and paclitaxel in esophagus cancer. Ann Oncol 15:960-965
5. Ajani JA, Moiseyenko VM, Tjulandin S et al (2007) Clinical benefit with doxetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal adenocarcinoma: the V-325 study group. J Clin Oncol 25:3205-3209
6. Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46
7. Shah MA, Jhawer M, Ilson DH et al (2010) Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 29:868-874
8. Wagner AD, Grothe W, Haerting J et al (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903-2909
9. Itakura Y, Sasano H, Shiga C et al (1994) Epidermal growth factor receptor overexpression in esophageal carcinoma. Cancer 74:795-804
10. Gibault L, Metges JP, Conan-Charlet V et al (2005) Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 93:107-115
11. Wang KL, Wu TT, Choi IS et al (2007) Expression of epidermal growth factor receptor in esophagus and esophagogastric junction adenocarcinomas. Associations with poor outcome. Cancer 109:658-667
12. Ekman S, Bergqvist M, Heldin CH, Lennartsson J (2007) Activation of growth factor receptors in esophageal cancer-implications for therapy. Oncologist 12:1165-1177
13. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500
14. Lynch TJ, BellDW, Sordella R et al (2004)Activatingmutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139
15. Kwak EL, Jankowski J, Thayer SP et al (2006) Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 12:4283-4287
16. Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246
17. Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 290:2149-2158
18. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
19. El-Maraghi RH, Eisenhauer EA (2008) Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. J Clin Oncol 26:1346-1354
20. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160-1174
21. Kurata T, Matsuo K, Takada M et al (2006) Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the secondline setting for advanced non-small cell lung cancer? J Thorac Oncol 1:684-691
22. Dragovich T, McCoy S, Fenoglio-Preiser CM et al (2006) Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 24:4922-4927
23. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA et al (2006) Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 24:1612-1619
24. Ferry DR, Anderson M, Beddard K et al (2007) A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 13:5869-5875
25. Ilson DH, Kelsen D, Shah M et al (2011) A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer 117:1409-1414
26. Tew WP, Kelsen DP, Ilson DH (2005) Targeted therapies for esophageal cancer. Oncologist 10:590-601
27. Pinto C, Di Fabio F, Siena S et al (2007) Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 18:510-517
28. Javle M, Pande A, Iyer R et al (2008) Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma. Tissue effect predicts clinical response. Am J Clin Oncol 31:329-334
29. Rodriguez CP, Adelstein DJ, Rice TW et al (2010) A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J Thorac Oncol 5:229-235
30. Ruhstaller T, Pless M, Dietrich D et al (2011) Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II trial (SAKK 75/06). J Clin Oncol 29:626-631
31. Rodriguez CP, Adelstein DJ, Saxton JP et al (2009) Multiagent concurrent chemoradiotherapy (MACCRT) and gefitinib in locoregionally advanced head and neck squamous cell cancer (HNSCC). J Clin Oncol 27:310s (suppl; abstr 6037)
32. Kelly K, Chansky K, Gaspar LE et al (2008) Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-smallcell lung cancer: SWOG S0023. J Clin Oncol 26:2450-2456
33. Hofmann M, Stoss O, Shi D et al (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52:797-805
34. Bang YJ, Van Custem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 376:687-697
35. Phillips BE, Tubbs RR, Rice TW et al (2011) Clinicopathologic features and treatment outcomes of patients (pts) with HER2-positive (pos) adenocarcinomas (ACA) of the esophagus (E) and gastroesophageal junction (GEJ). J Clin Oncol 29:65 (suppl. 4; abstr 71)